Timber Hill’s Regeneron Pharmaceuticals REGN Stock Holding History

Timber Hill’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,892	Closed	-$652K	–	231
2018 Q1	$652K	Buy	+1,892	New	+$658K	0.1%	148
2015 Q4	–	Sell	-8,612	Closed	-$4.67M	–	2434
2015 Q3	$4.01M	Buy	8,612 +7,864	+1,051%	+$4.22M	0.02%	657
2015 Q2	$382K	Buy	+748	New	+$365K	﹤0.01%	2044
2015 Q1	–	Sell	-787	Closed	-$334K	–	2585
2014 Q4	$323K	Buy	+787	New	+$309K	﹤0.01%	2124
2014 Q2	–	Sell	-2,276	Closed	-$675K	–	2919
2014 Q1	$683K	Sell	2,276 -2,160	-49%	-$665K	﹤0.01%	1853
2013 Q4	$1.22M	Sell	4,436 -5,649	-56%	-$1.62M	﹤0.01%	1686
2013 Q3	$3.15M	Buy	+10,085	New	+$2.65M	0.01%	1139

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Timber Hill's REGN Position: Q2 2018 in Review

Timber Hill sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 1,892 shares — an estimated $652K sold.

Timber Hill first reported a position in REGN in Q3 2013 and held it in 7 quarters. The position peaked at $4.01M in Q3 2015. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

Timber Hill reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Timber Hill sold 1,892 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $652K.
Timber Hill first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Timber Hill's Regeneron Pharmaceuticals position peaked at $4.01M in Q3 2015.
624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.